https://sputnikglobe.com/20211022/pfizer-says-covid-19-vaccine-over-90-effective-in-children-1090137219.html
Pfizer Says COVID-19 Vaccine Over 90% Effective in Children
Pfizer Says COVID-19 Vaccine Over 90% Effective in Children
Sputnik International
WASHINGTON (Sputnik) – The Pfizer/BioNTech COVID-19 vaccine has shown more than 90% efficacy in children between 5 and 11 years old, according to a study... 22.10.2021, Sputnik International
2021-10-22T14:13+0000
2021-10-22T14:13+0000
2021-10-22T14:13+0000
pfizer
vaccine
covid-19
https://cdn1.img.sputnikglobe.com/img/07e5/08/18/1083703620_0:136:3161:1914_1920x0_80_0_0_23dd8335783f609bc2eaf9f93efaebca.jpg
"The observed VE [vaccine effectiveness] from at least 7 days after Dose 2 for BNT162b2 10 µg administered to children 5 to <12 years of age without prior evidence of SARS-CoV-2 infection before or during the vaccination regimen, per protocol case criteria (refer to Section 7) was 90.7%," the report said.Both companies promised that benefits of the vaccine outweigh the known or potential risks. They have acknowledged, however, the possibility of post-vaccination myocarditis among children between ages 5 and 11.The FDA is expected to release its review of Pfizer's data on Friday, according to media reports.
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
pfizer, vaccine, covid-19
pfizer, vaccine, covid-19
Pfizer Says COVID-19 Vaccine Over 90% Effective in Children
WASHINGTON (Sputnik) – The Pfizer/BioNTech COVID-19 vaccine has shown more than 90% efficacy in children between 5 and 11 years old, according to a study submitted to the US Food and Drug Administration.
"The observed VE [vaccine effectiveness] from at least 7 days after Dose 2 for BNT162b2 10 µg administered to children 5 to <12 years of age without prior evidence of SARS-CoV-2 infection before or during the vaccination regimen, per protocol case criteria (refer to Section 7) was 90.7%," the report said.
Both companies promised that benefits of the vaccine outweigh the known or potential risks. They have acknowledged, however, the possibility of post-vaccination myocarditis among children between ages 5 and 11.
The FDA is expected to release its review of Pfizer's data on Friday, according to media reports.
